Ascendiant Downgrades Cytori Therapeutics As ATHENA Trials Are Put On Hold
Ascendiant Capital lowered its Buy rating to Hold on Cytori Therapeutics (NASDAQ: CYTX).
Ascendiant Capital mentioned that the ATHENA trials were put on clinical hold:
“The Company has announced that it has placed enrollment in the ATHENA and ATHENA II trials on clinical hold. This decision was based on a safety review that reported cerebrovascular events had occurred in 3 patients enrolled in the ATHENA study.”
Ascendiant Capital also mentioned that a secondary capital offering will be necessary for Cytori to stay solvent:
“Cytori Therapeutics ended Q1 2014 with $12.8 MM in cash. This compares to $22 MM at the end of 2013. We believe that the company will need to raise additional cash in the future. Now that the ATHENA studies are on hold, we would anticipate that R&D expense will decrease, which should reduce the cash burn from operation, which lately has been around $9 MM per quarter.”
Cytori Therapeutics were last trading at $1.67, down 20.48 percent.
Latest Ratings for CYTX
|Dec 2016||B. Riley||Initiates Coverage On||Buy|
|May 2015||Ascendiant Capital||Initiates Coverage on||Buy|
|Aug 2014||Ascendiant Capital||Downgrades||Buy||Hold|
© 2017 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.